News

Tysabri (natalizumab) significantly reduced the development of brain lesions on MRI scans in Japanese people with relapsing-remitting multiple sclerosis (RRMS), according to a new study. The therapy also eased or stabilized disability levels in most patients after five years of treatment, and significantly reduced the annual rate of…

Researchers at the Kessler Foundation have received $725,499 from the National Multiple Sclerosis Society to study how to improve learning and memory in multiple sclerosis (MS). The team will use the funding to evaluate the benefits of a cognitive intervention called COMBINE, which involves cognitive training and…

Health technology platform Folia Health is expanding patient-reported data collection in multiple sclerosis (MS), Huntington’s disease (HD), and myasthenia gravis (MG), a move the company hopes will lead to collaborative observational research in the complex disorders, and help transform research and care. As part of this…

Note: This story was updated Sept. 15, 2023, to clarify ANK-700 was developed based on the preclinical work described in the study. An “inverse vaccine” that’s designed to teach the immune system not to attack a specific target, effectively reduced disease activity in mouse models of multiple sclerosis (MS),…

Greater self-reported physical disability within the first years of being diagnosed with relapsing-remitting multiple sclerosis (MS) is associated with a higher likelihood of transitioning to a progressive form of the disease. The finding comes from a recent analysis of patient-reported data from the U.K. MS Register. Scientists believe the…

People with multiple sclerosis (MS) are about two times more likely to have migraines than healthy people while migraines affect around 24% of people with the neurodegenerative condition, a recent meta-analysis suggests. The mechanisms behind the higher risk in MS, “continue to elude us, and further investigation is warranted…

People with multiple sclerosis (MS) who receive vaccines against influenza — commonly known as flu shots — as well as diphtheria, polio, pneumoccocus, and multiple other pathogens are not significantly more likely to be hospitalized due to a disease relapse, according to a new study in France. Similar…

Octave Bioscience plans to test its precision care program in an observational, real-world study with people with multiple sclerosis (MS). The program, called MS Precision Care Solution, uses blood biomarkers to monitor disease activity alongside MRI scans of the brain and spinal cord. An app tracks…

A new statistical method could help to more accurately capture changes in disability severity for people with multiple sclerosis (MS) and monitor the impact of MS treatments. “With the use of this new statistical methodology, it is possible to estimate the time to improvement as well as the…

Innodem Neurosciences has signed a multi-year agreement with Novartis Canada to continue developing Innodem’s digital biomarker eye-tracking technology, a noninvasive method to monitor disease progression in multiple sclerosis (MS). The multimillion-dollar commercial agreement comes on the heels of promising data from an observational trial, sponsored by…

A protein called Daam2 helps to regulate the activity of cells in the brain that make myelin, the fatty covering around nerve fibers that’s damaged in multiple sclerosis (MS), a new study shows. By uncovering how that protein functions in the brain to boost myelin repair, researchers have discovered…

An anti-inflammatory diet combined with synbiotic supplements eased fatigue, pain, sexual dysfunction, and bladder and bowel problems in people with progressive forms of multiple sclerosis (MS) in a small clinical trial. Synbiotics contain probiotics, healthy bacteria for the gut, and prebiotics, or plant fibers that feed probiotics and help…

Bowel symptoms go largely unreported among people with multiple sclerosis (MS), mostly due to the unwillingness of patients to talk about their symptoms with their doctors, according to a recent study. However, a self-reported questionnaire called Neurogenic Bowel Dysfunction (NBD) may help screen patients for bowel symptoms without the…

An energy management education program combined with high-intensity exercise during a three-week inpatient rehabilitation program didn’t lead to quality of life gains for multiple sclerosis (MS) patients with fatigue over usual care, but it did offer some benefit. In the months after the program, better cardiorespiratory fitness, gains in…

A test that assesses the levels of 18 proteins in the blood and uses artificial intelligence algorithms can help to measure the level of new disease activity in multiple sclerosis (MS), according to a new study. The test, developed by …

Ocrevus (ocrelizumab) will be funded in New Zealand for treating certain people with primary progressive multiple sclerosis (PPMS) about six years after being approved there. The decision from the Pharmaceutical Management Agency (Pharmac), which decides what medicines are funded in New Zealand and to what extent, makes Ocrevus…

Total Teen Burger purchases netted $1.6 million for MS Canada on A&W Canada’s 15th Annual Burgers to Beat MS Day. Proceeds from the Aug. 17 fundraiser, wherein A&W donated $2 from each burger sold, brings to more than $20 million the amount the initiative has brought…

Four researchers working in multiple sclerosis (MS) were awarded incubator grants in MS Australia’s latest funding round, which they’ll use to kickstart projects designed to better understand the progressive neurodegenerative disease. Worth a total of AU$92,565, or roughly $60,000, this round of incubator grants provides seed funding…

Noting that Aubagio (teriflunomide) continues to have “a robust impact on disability progression” in multiple sclerosis (MS) despite being eclipsed by newer MS treatments in trials, an international team of researchers are now arguing that it is, in fact, still ethical to use the older therapy as a…

Octave Bioscience was selected as a finalist in this year’s Innovation by Design Awards in recognition of the platform it created to improve the care of people with multiple sclerosis (MS). Organized by the media brand Fast Company, the awards are touted as some of the most sought-after…

A course of neuromuscular electrical stimulation using Neufit‘s neuro-bio-electric stimulator — a device dubbed Neubie — alongside physical therapy (PT) led to improvements in strength and range of motion for seven people with multiple sclerosis (MS), according to a case series. Use of the Neubie device and PT…

Nura Bio has launched a Phase 1 clinical trial evaluating NB-4746, its investigational treatment for multiple sclerosis (MS) and several other neurological conditions, in healthy volunteers. The trial’s participants will be randomly assigned to receive single and multiple doses of NB-4746 or a placebo. The goal is to…

A new system that can use MRI scans to effectively measure myelin content in brain tissue may help assess the progression of multiple sclerosis (MS) and evaluate the effectiveness of treatments. The technique was described in “Quantitative magnetic resonance mapping of the myelin bilayer,” which…

Cionic’s Neural Sleeve, a leg-worn garment designed to boost strength and walking performance in people with conditions such as multiple sclerosis (MS), has won multiple awards in this year’s International Design Excellence Awards program. The event, organized by the Industrial Designers Society of America (IDSA), is touted as one of…

Diagnosing primary progressive multiple sclerosis (PPMS) can be challenging, with obstacles ranging from ruling out other disorders to differentiating between PPMS and other types of multiple sclerosis (MS). These difficulties were highlighted in the study, “Real-world challenges in the diagnosis of primary progressive multiple sclerosis,” published…

The presence of lesions, or regions of damage, in a brain circuit tied to memory in stroke patients also associate with memory problems in multiple sclerosis (MS), a study shows. Findings may help to determine which lesions are likely to cause memory issues in people with the neurodegenerative condition,…

The U.S. Food and Drug Administration (FDA) has approved Tyruko (natalizumab-sztn) as the first biosimilar of Tysabri to treat adults with relapsing forms of multiple sclerosis (MS). The decision also marks the first approval of any biosimilar for MS in the country, according to the regulatory agency.

Treatment with polysialic acid, a sugar molecule naturally made in the body, may be a promising approach to boost myelin repair in people with multiple sclerosis (MS), according to a new study in lab-grown brain samples. Findings show that the molecule increased myelin repair, or remyelination, in the cell…

A day of golfing is in store for those who want to support Johns Hopkins Hospital’s efforts on behalf of research for multiple sclerosis (MS) and to raise awareness about the progressive neurodegenerative disorder. The #spreadingORANGE event will aid the Johns Hopkins Multiple Sclerosis Center along with MS…

ASH41020, an investigational therapy from Ashvattha Therapeutics, significantly reduced disease severity and exhibited immunomodulatory properties in a mouse model of multiple sclerosis (MS), according to a recent presentation. Evidence indicated the therapy works by shifting the balance of immune cells called macrophages toward a less inflammatory and more…